Healthcare [ 12/13 ] | Diagnostics & Research [ 56/164 ]
NASDAQ | Common Stock
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products.
The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution.
In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses.
Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody.
The company was incorporated in 2013 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | -0.79 Increased by +24.04% | -0.82 Increased by +3.66% |
| Mar 12, 24 | -0.75 Decreased by -1.35% | -0.78 Increased by +3.85% |
| Nov 17, 23 | -0.81 Increased by +10.99% | -0.92 Increased by +11.96% |
| Aug 4, 23 | -0.78 Increased by +27.78% | -1.14 Increased by +31.58% |
| May 5, 23 | -1.04 Increased by +7.96% | -1.12 Increased by +7.14% |
| Feb 3, 23 | -0.74 Increased by +18.68% | -1.13 Increased by +34.51% |
| Nov 18, 22 | -0.91 Decreased by -8.33% | -1.25 Increased by +27.20% |
| Aug 5, 22 | -1.08 Decreased by -38.46% | -1.31 Increased by +17.56% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 75.30 M Increased by +25.13% | -45.49 M Increased by +23.10% | Decreased by -60.41% Increased by +38.54% |
| Dec 31, 23 | 71.50 M Increased by +31.81% | -43.01 M Decreased by -2.83% | Decreased by -60.15% Increased by +21.99% |
| Sep 30, 23 | 66.95 M Increased by +16.82% | -46.24 M Increased by +9.53% | Decreased by -69.08% Increased by +22.56% |
| Jun 30, 23 | 63.74 M Increased by +13.59% | -57.40 M Increased by +5.16% | Decreased by -90.05% Increased by +16.51% |
| Mar 31, 23 | 60.18 M Increased by +25.04% | -59.16 M Increased by +2.49% | Decreased by -98.30% Increased by +22.02% |
| Dec 31, 22 | 54.24 M Increased by +29.09% | -41.82 M Increased by +8.21% | Decreased by -77.10% Increased by +28.89% |
| Sep 30, 22 | 57.31 M Increased by +51.00% | -51.12 M Decreased by -23.95% | Decreased by -89.20% Increased by +17.92% |
| Jun 30, 22 | 56.11 M Increased by +60.24% | -60.52 M Decreased by -51.15% | Decreased by -107.85% Increased by +5.67% |